文献速递糖尿病肥胖与代谢综合征

卡格列净可减轻高心血管风险2型糖尿病患者的CMR量化心肌纤维化:一项随机开放标签对照试验

Canagliflozin attenuates CMR-quantified myocardial fibrosis in individuals with type 2 diabetes mellitus at high cardiovascular risk: a randomised open-label controlled trial.
PubMed 文献 · Diabetologia · 2026-02-24

本研究为开放标签平行随机对照试验,纳入45例高心血管风险2型糖尿病患者,随机接受卡格列净100mg/日或西格列汀100mg/日治疗26周。主要终点为心脏磁共振量化细胞外容积(ECV)变化,结果显示卡格列净较西格列汀显著降低ECV(校正均差-3.67%,95%CI -5.33至-2.01,p<0.001),并改善左室舒张末期容积等心脏结构指标,为SGLT2抑制剂心血管保护机制提供影像学证据。

要点

  • 卡格列净治疗26周显著降低高心血管风险2型糖尿病患者的CMR量化ECV。
  • 卡格列净还改善左室舒张末期容积和超声衍生舒张末期内径。
  • 两组HbA1c降幅相当,提示心脏获益不完全依赖血糖控制。

核心结论

  • 26周卡格列净治疗显著降低高心血管风险2型糖尿病患者的CMR衍生ECV,提示减轻心肌纤维化。

研究设计与样本

  • 开放标签平行随机对照试验,纳入45例18-75岁高心血管风险2型糖尿病患者,1:1随机接受卡格列净100mg/日(n=23)或西格列汀100mg/日(n=22)治疗26周。

主要发现

  • 26周时,卡格列净较西格列汀显著降低主要终点ECV(校正均差-3.67%;95%CI -5.33至-2.01;p<0.001)。
  • 卡格列净较西格列汀显著改善左室舒张末期容积(校正均差-20.72 ml;95%CI -36.30至-5.14;p=0.010)。
  • 卡格列净较西格列汀显著改善超声衍生舒张末期内径(校正均差-2.82 mm;95%CI -4.95至-0.70;p=0.010)。
  • 两组HbA1c降幅相当(均下降0.7%,组间p=0.972)。

关键数值与推荐

  • 主要终点为CMR量化ECV变化。
  • 次要终点包括左室舒张末期容积、左室舒张末期内径、左室射血分数等心室结构与功能参数。

临床怎么用

  • 对于高心血管风险2型糖尿病患者,卡格列净可能通过减轻心肌纤维化带来心脏结构获益,且不依赖血糖降幅差异。

局限性

  • 开放标签设计,参与者和照护者知晓分组,但结果评估者和数据分析者设盲。
  • 样本量较小(45例完成意向性分析),研究期间为26周。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: We aimed to investigate canagliflozin's effects on myocardial fibrosis, cardiac structure and function, and microcirculation in high-cardiovascular-risk type 2 diabetes mellitus through cardiac magnetic resonance (CMR) quantification, while investigating the cardiovascular protective mechanisms of sodium-glucose cotransporter 2 (SGLT2) inhibitors. METHODS: This open-label parallel RCT recruited 45 high-risk participants (18-75 years) with type 2 diabetes (HbA1c 53.0-91.3 mmol/mol [7.0-10.5%]) and left ventricular ejection fraction (LVEF) >50% from the Endocrinology Outpatient Clinic of Zhongshan Hospital, Fudan University (August 2022 to November 2024). Participants were 1:1 randomised via a computer-generated sequence through the centralised iClinicalStation system (allocation concealed, performed by independent personnel not involved in outcome assessment). They received canagliflozin 100 mg/day (n=23) or sitagliptin 100 mg/day (n=22) for 26 weeks. Consistent with the open-label design, participants and care providers were aware of treatment assignments; however, outcome assessors (radiologists, sonographers) and data analysts remained blinded to group allocation to minimise bias. The primary endpoint was CMR-quantified extracellular volume (ECV) change. Secondary outcomes included ventricular structure and function parameters, for example, left ventricular end-diastolic volume, left ventricular end-diastolic diameter, LVEF, etc. RESULTS: Among 67 individuals screened, 45 completed the intention-to-treat analysis (age 60.4 ± 9.7 years, BMI 26.4 ± 2.6 kg/m2, HbA1c 63.0 ± 8.7 mmol/mol [7.9 ± 0.8%]). At 26 weeks, compared with sitagliptin, canagliflozin significantly reduced the primary outcome of ECV (adjusted mean difference [AMD]: -3.67%; 95% CI -5.33, -2.01; p<0.001). Significant improvements were also observed in cardiac structure, including left ventricular end-diastolic volume (AMD: -20.72 ml; 95% CI -36.30, -5.14; p=0.010) and echocardiography-derived end-diastolic diameter (AMD: -2.82 mm; 95% CI -4.95, -0.70; p=0.010). Both groups showed comparable reductions in HbA1c (both Δ 0.7%, inter-group p=0.972). CONCLUSIONS/INTERPRETATION: This study demonstrates that 26 weeks of canagliflozin significantly reduces myocardial fibrosis, as assessed by CMR-derived ECV, in individuals with type 2 diabetes at high cardiovascular risk, providing imaging evidence for SGLT2 inhibitor cardiovascular protection mechanisms. TRIAL REGISTRATION: ClinicalTrials.gov NCT05367063 FUNDING: This study was financially supported by the National Key Research and Development programme (2023YFA1802000), the National Natural Science Foundation of China (Youth Fund 82200909), the Young and Middle-aged Diabetes project from the Bethune Foundation (Z04JKM2022E002), the Joint Research Development project between Shenkang and United Imaging on Clinical Research and Translation (SKLY2022CRT201), the Shanghai Municipal 'Explorer plan' (the second batch) project in 2024 (24TS1411000) and the Shanghai pujiang programme (21PJD012).

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Yan H, Liu J, Zhang Z, et al. Canagliflozin attenuates CMR-quantified myocardial fibrosis in individuals with type 2 diabetes mellitus at high cardiovascular risk: a randomised open-label controlled trial. Diabetologia. 2026. PMID: 41735586. doi:10.1007/s00125-026-06682-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。